风湿免疫科

订阅

MedSci主页 / 所有栏目 / 风湿免疫科

Coherus宣布与AbbVie达成全球和解，确保其Adalimumab生物仿制药CHS-1420商业化的权利

2019-01-29 MedSci MedSci原创

CHS-1420CoherusAdalimumab生物仿制药
关注

Coherus是一家生物仿制药公司，近日宣布已与AbbVie达成和解协议，该协议授予Coherus在AbbVie知识产权下的全球非独家许可权，以将CHS-1420（阿达木单抗，Adalimumab生物仿制药）商业化。

Coherus是一家生物仿制药公司，近日宣布已与AbbVie达成和解协议，该协议授予Coherus在AbbVie知识产权下的全球非独家许可权，以将CHS-1420（阿达木单抗，Adalimumab生物仿制药）商业化。全球和解解决了与Coherus的阿达木单抗生物仿制药相关的所有未决争议。根据美国和解协议，Coherus在美国的执照期限于2023年12月15日开始。Cherherus将向AbbVie支付版税。

Coherus董事长兼首席执行官兼总裁Denny Lanfear说：“生物仿制药在我们的医疗保健系统中发挥着重要作用，可以抑制成本增加，同时扩大患者的使用范围。我们希望通过自己的销售队伍推出CHS-1420，并在此后实现显著的收入增长”。CHS-1420是Coherus为有需要的患者提供高价值治疗的众多重要生物仿制药候选者之一，其中包括该公司针对Enbrel，Lucentis和Eylea的生物仿制药候选药物。该公司目前正在准备其CHS-1420的生物制剂许可申请，提交给美国食FDA，预计将于2019年末提交申请。


原始出处：

http://www.firstwordpharma.com/node/1620853#axzz5dfw0Z0Ih

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1771791, encodeId=00dd1e717917f, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Apr 13 14:54:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912077, encodeId=a8b019120e736, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jan 12 08:54:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261469, encodeId=f333126146966, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264682, encodeId=611d126468228, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412925, encodeId=ead11412925fc, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477867, encodeId=864114e7867e4, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479588, encodeId=746814e95887f, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506759, encodeId=9be91506e596a, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624312, encodeId=4e701624312be, content=<a href='/topic/show?id=fce719342b' target=_blank style='color:#2F92EE;'>#Adalimumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1934, encryptionId=fce719342b, topicName=Adalimumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eee520667499, createdName=ay2007fy, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-04-13 zhangxingru

    #商业#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1771791, encodeId=00dd1e717917f, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Apr 13 14:54:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912077, encodeId=a8b019120e736, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jan 12 08:54:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261469, encodeId=f333126146966, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264682, encodeId=611d126468228, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412925, encodeId=ead11412925fc, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477867, encodeId=864114e7867e4, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479588, encodeId=746814e95887f, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506759, encodeId=9be91506e596a, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624312, encodeId=4e701624312be, content=<a href='/topic/show?id=fce719342b' target=_blank style='color:#2F92EE;'>#Adalimumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1934, encryptionId=fce719342b, topicName=Adalimumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eee520667499, createdName=ay2007fy, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2020-01-12 snf701207

    #mAb#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1771791, encodeId=00dd1e717917f, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Apr 13 14:54:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912077, encodeId=a8b019120e736, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jan 12 08:54:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261469, encodeId=f333126146966, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264682, encodeId=611d126468228, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412925, encodeId=ead11412925fc, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477867, encodeId=864114e7867e4, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479588, encodeId=746814e95887f, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506759, encodeId=9be91506e596a, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624312, encodeId=4e701624312be, content=<a href='/topic/show?id=fce719342b' target=_blank style='color:#2F92EE;'>#Adalimumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1934, encryptionId=fce719342b, topicName=Adalimumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eee520667499, createdName=ay2007fy, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-01-31 drwjr

    #仿制药#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1771791, encodeId=00dd1e717917f, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Apr 13 14:54:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912077, encodeId=a8b019120e736, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jan 12 08:54:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261469, encodeId=f333126146966, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264682, encodeId=611d126468228, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412925, encodeId=ead11412925fc, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477867, encodeId=864114e7867e4, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479588, encodeId=746814e95887f, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506759, encodeId=9be91506e596a, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624312, encodeId=4e701624312be, content=<a href='/topic/show?id=fce719342b' target=_blank style='color:#2F92EE;'>#Adalimumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1934, encryptionId=fce719342b, topicName=Adalimumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eee520667499, createdName=ay2007fy, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-01-31 般若傻瓜

    #ADA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1771791, encodeId=00dd1e717917f, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Apr 13 14:54:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912077, encodeId=a8b019120e736, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jan 12 08:54:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261469, encodeId=f333126146966, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264682, encodeId=611d126468228, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412925, encodeId=ead11412925fc, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477867, encodeId=864114e7867e4, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479588, encodeId=746814e95887f, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506759, encodeId=9be91506e596a, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624312, encodeId=4e701624312be, content=<a href='/topic/show?id=fce719342b' target=_blank style='color:#2F92EE;'>#Adalimumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1934, encryptionId=fce719342b, topicName=Adalimumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eee520667499, createdName=ay2007fy, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-01-31 grace5701

    #生物仿制药#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1771791, encodeId=00dd1e717917f, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Apr 13 14:54:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912077, encodeId=a8b019120e736, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jan 12 08:54:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261469, encodeId=f333126146966, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264682, encodeId=611d126468228, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412925, encodeId=ead11412925fc, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477867, encodeId=864114e7867e4, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479588, encodeId=746814e95887f, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506759, encodeId=9be91506e596a, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624312, encodeId=4e701624312be, content=<a href='/topic/show?id=fce719342b' target=_blank style='color:#2F92EE;'>#Adalimumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1934, encryptionId=fce719342b, topicName=Adalimumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eee520667499, createdName=ay2007fy, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-01-31 ms3117646317107274

    #S-1#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1771791, encodeId=00dd1e717917f, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Apr 13 14:54:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912077, encodeId=a8b019120e736, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jan 12 08:54:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261469, encodeId=f333126146966, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264682, encodeId=611d126468228, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412925, encodeId=ead11412925fc, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477867, encodeId=864114e7867e4, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479588, encodeId=746814e95887f, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506759, encodeId=9be91506e596a, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624312, encodeId=4e701624312be, content=<a href='/topic/show?id=fce719342b' target=_blank style='color:#2F92EE;'>#Adalimumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1934, encryptionId=fce719342b, topicName=Adalimumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eee520667499, createdName=ay2007fy, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-01-31 12498768m15(暂无昵称)

    #Abbvie#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1771791, encodeId=00dd1e717917f, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Apr 13 14:54:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912077, encodeId=a8b019120e736, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jan 12 08:54:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261469, encodeId=f333126146966, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264682, encodeId=611d126468228, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412925, encodeId=ead11412925fc, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477867, encodeId=864114e7867e4, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479588, encodeId=746814e95887f, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506759, encodeId=9be91506e596a, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624312, encodeId=4e701624312be, content=<a href='/topic/show?id=fce719342b' target=_blank style='color:#2F92EE;'>#Adalimumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1934, encryptionId=fce719342b, topicName=Adalimumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eee520667499, createdName=ay2007fy, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-01-31 yeaweam

    #商业化#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1771791, encodeId=00dd1e717917f, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Apr 13 14:54:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912077, encodeId=a8b019120e736, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jan 12 08:54:00 CST 2020, time=2020-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261469, encodeId=f333126146966, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264682, encodeId=611d126468228, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412925, encodeId=ead11412925fc, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477867, encodeId=864114e7867e4, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479588, encodeId=746814e95887f, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506759, encodeId=9be91506e596a, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40064, encryptionId=afce40064d1, topicName=商业化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b549798360, createdName=yeaweam, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624312, encodeId=4e701624312be, content=<a href='/topic/show?id=fce719342b' target=_blank style='color:#2F92EE;'>#Adalimumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1934, encryptionId=fce719342b, topicName=Adalimumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eee520667499, createdName=ay2007fy, createdTime=Thu Jan 31 06:54:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-01-31 ay2007fy

    #Adalimumab#

    0